Astellas to Test Selecta’s IgG Protease with Pompe Gene Therapy

Astellas Pharma is getting its hands on US peer Selecta Biosciences’ next-generation IgG protease candidate, betting on the drug’s potential for combined use with its gene therapy for Pompe disease, which is now under an FDA clinical hold. The two...read more